Stopping the medicine can sometimes cause weight gain, which can feel frustrating
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily prescribed for managing type 2 diabetes and, in specific formulations, for weight management in adults with obesity
The injectable obesity medications Semaglutide 2.4 mg, a selective GLP-1 receptor agonist, produces robust and durable weight loss of approximately 1516% over 68 weeks ( Tirzepatide, a dual gastric inhibitory polypeptide (GIP)/GLP-1 receptor agonist, delivers even greater weight loss, exceeding 20% at the highest dose in pivotal trials ( Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, represents a further step in efficacy, with 24.2% weight loss achieved within 48 weeks in phase 2 studies ( Survodutide, an oxyntomodulin analogue, achieved clinically meaningful weight loss ( Table 2
Similarly, trials with GLP-1 agonists and sodium-glucose cotransporter 2 inhibitors have reported favorable effects on renal function, even after only 34 years of treatment
Enrollment in our plans depends on contract renewal